Key result
S-GRAS score outperforms individual components in predicting progression-free and disease-specific survival.
Why the study?
Prognostic stratification of adrenocortical carcinoma based on ENSAT stage and Ki67 index is limited, necessitating improved prognostic tools.
Does the S-GRAS score improve prognostic stratification for progression-free and disease-specific survival in patients with adrenocortical carcinoma compared to individual components?
Population
942 ACC patients who underwent adrenalectomy
Comparison
S-GRAS score vs individual components including tumour stage and Ki67 index
Design
Multicentre retrospective cohort study
Loading...
S-GRAS may refine post-adrenalectomy risk stratification in ACC; leaves open superiority to ENSAT/Ki67 in prospective cohorts.
Cohort (n=942)
Yes
Does the S-GRAS score improve prognostic stratification for progression-free and disease-specific survival in patients with adrenocortical carcinoma compared to individual components?
Effect estimate: C-index 0.73 (PFS) and 0.79 (DSS)
p-value: p=<0.01
The S-GRAS score provides superior prognostic stratification for progression-free and disease-specific survival in patients with adrenocortical carcinoma compared to traditional staging and Ki67 index.
A 2021 study conducted a cohort in Adrenocortical carcinoma (ACC) (n=942). S-GRAS score vs. Individual components (tumour stage, Ki67 index, resection status, age, symptoms) was evaluated on Progression-free survival (PFS) and disease-specific survival (DSS) (C-index 0.73 (PFS) and 0.79 (DSS), p=<0.01). The S-GRAS score demonstrated superior prognostic performance for progression-free survival (C-index 0.73) and disease-specific survival (C-index 0.79) compared to individual components (P<0.01).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: